Dual I-O treatment continues to show benefit after three years
Bristol Myers Squibb (NYSE: BMY) is to present new three-year data from the CheckMate-743 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) at the European Society of Medical Oncology’s (ESMO) annual congress.
The ongoing trial continues to show the sustained survival benefits that can be provided through the use of dual immunotherapy in multiple tumor types, including non-small cell lung cancer (NSCLC).
At ESMO 2021, Bristol Myers will present results which show the combo produced a durable survival benefit, compared with chemo, in people with unresectable malignant pleural mesothelioma (MPM).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze